Tiziana Life Sciences Reports Positive 6-month Data With Intranasal Foralumab In Multiple Sclerosis

Tiziana Life Sciences Ltd. (TLSA), a clinical-stage biopharmaceutical company, announced Monday positive six-month clinical results in multiple sclerosis patients treated with intranasal Foralumab.

Related Keywords

Gabriele Cerrone ,Access Program ,More Such Health News ,Research Of Multiple Sclerosis On ,Tiziana Life Sciences ,Tiziana Life Sciences Ltd ,European Committee For Treatment ,Modified Fatigue Impact Scale ,Secondary Progressive Multiple Sclerosis ,Expanded Access ,European Committee ,Multiple Sclerosis ,Foralumab ,Intranasal Foralumab ,